Compare Quest Diagnostics Inc (DGX) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Block Inc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Block Inc trades at $77.24 (market cap $45.20B). The key difference: Block Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Block Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Block Inc for 78 Days on average.
| DGX | XYZ | |
|---|---|---|
Market Cap | $25.48B | $45.20B |
Volume | 941,866 | 8,386,094 |
Sector | Health | Technology |
52-Week High | $247.45 | $84.85 |
52-Week Low | $173.49 | $49.04 |
Typical Hold Time | 56 Days | 78 Days |
Enterprise Value | $31.23B | $40.10B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
Block (XYZ) trades at $77.24, up 1.54% today, with strong analyst support (77% buy ratings) and a $97.47 consensus price target suggesting 26% upside. Recent quarters show earnings momentum with Q1 and Q2 2026 beats, though Q3 2026 results are pending. Revenue growth has been steady, reaching $24.19B in 2025, but net margins remain thin at 1.43%. Technical indicators are bearish overall, with the stock testing resistance near $77.
The stock offers growth potential from expanding Square and Cash App ecosystems and new banking initiatives, but faces risks from high P/E valuation (134.34), competitive pressures, and insider selling. Positive earnings surprises and institutional accumulation provide support, though profitability consistency and debt levels warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
